drugset / Trial / NCT02758067

Comparison of the Effectiveness of Brexpiprazole With That of Risperidone

NCT02758067

RandomizedParallel-groupDouble-blindTreatment

Summary

To demonstrate that the effectiveness of brexpiprazole (2-4 mg/day) on quality of life is non-inferior to that of risperidone (4-6 mg/day) in adult patients with schizophrenia.

Timeline

Start
2016-06
Primary completion
2016-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Brexpiprazole Small molecule 2 mg Oral
Subject Brexpiprazole Small molecule 4 mg Oral
Subject Risperidone Other / unclassified 4 mg Oral
Subject Risperidone Other / unclassified 6 mg Oral

Indications